Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 15 of 52 for:    "Acute Leukemia" | "Anti-Bacterial Agents"

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02914977
Recruitment Status : Active, not recruiting
First Posted : September 26, 2016
Last Update Posted : June 24, 2019
Sponsor:
Information provided by (Responsible Party):
Tara Lin, University of Kansas Medical Center

Brief Summary:
In this pilot study, eligible patients will be treated with 5 days of low dose daunorubicin for one cycle only. Any patient who receives treatment on this protocol will be evaluable for toxicity. Each patient will be assessed for the development of toxicity at all scheduled visits (Days 1-5). Following participation on this brief pharmacodynamic trial, patients can then proceed to other conventional or investigational therapies, as clinically indicated.

Condition or disease Intervention/treatment Phase
Acute Lymphocytic Leukemia Acute Myeloid Leukemia Drug: Daunorubicin Phase 1

Detailed Description:

Disease relapse remains the primary challenge in the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). There is no standard of care treatment option for relapsed acute leukemia, and investigational therapies are recommended. Clinically targeting the leukemia stem cell (LSC) remains an unmet need in both AML and ALL. Therefore, a primary objective of this trial is to determine the molecular pharmacodynamic effects of low dose daunorubicin (DNR) on beta-catenin phosphorylation in serial bone marrow samples of patients with relapsed leukemia.

Prior to studying low-dose DNR in complex, multi-agent regimens, it is essential to confirm that it inhibits p-beta-catenin S552 in humans. This pilot study is designed to assess the feasibility and tolerability of low dose DNR administration to patients with relapsed/refractory AML and ALL, and obtain preliminary data regarding target engagement. A second objective is to demonstrate the safety and feasibility of low-dose daunorubicin administration in patients with relapsed/refractory acute leukemia.

Beta-catenin phosphorylation will be measured by immunohistochemistry assay in bone marrow samples taken from patients at study entry and at Day 8 following study therapy with low-dose DNR. The investigators will also measure the pharmacokinetics of low dose DNR in these patients, to enable preliminary PK-PD analyses and because there are essentially no PK data for DNR at comparable doses using modern analytical methodologies.

Following participation on this brief pharmacodynamic proof-of-concept trial, patients can then proceed to other conventional or investigational therapies, as clinically indicated.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia
Actual Study Start Date : November 2016
Actual Primary Completion Date : April 3, 2019
Estimated Study Completion Date : November 2020


Arm Intervention/treatment
Experimental: Low-dose daunorubicin (DNR)
Eligible patients will be treated with 5 days of low dose daunorubicin (DNR) for one cycle only.
Drug: Daunorubicin
  • Agent: Daunorubicin
  • Dose: 6.75 mg/m2/day
  • Route: IV
  • Schedule: Days 1-5
  • Duration: One cycle
Other Names:
  • Cerubidine
  • Daunoxome




Primary Outcome Measures :
  1. Molecular pharmacodynamic effect of low dose daunorubicin on beta-catenin phosphorylation as assessed by quantitative immunohistochemistry assay performed on serial bone marrow samples of patients with relapsed leukemia. [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events and/or toxicity as assessed by CTCAE 4.03. [ Time Frame: 12 months ]
    Analyses will be performed for all patients having received at least one dose of study drug. Each patient will be assessed for the development of toxicity at all scheduled visits (Days 1-5).

  2. Maximum Plasma Concentration [Cmax] [ Time Frame: prior to dosing and 5, 20, and 40 min and 1, 2, 4, 8, and 24 hrs after dosing ]
  3. Area Under the Curve [AUC] [ Time Frame: prior to dosing and 5, 20, and 40 min and 1, 2, 4, 8, and 24 hrs after dosing ]

Other Outcome Measures:
  1. Test for additional validated markers for leukemia and/or stem cells (such as anti-CD34 and CD38, CD45 and/or CD19) assessed by flow cytometry of serial bone marrow samples. [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to understand and the willingness to sign a written informed consent or have parental consent.
  • Age ≥ 18 years
  • Pathological confirmation by bone marrow documenting the following:

    1. AML which has relapsed after Complete Remission
    2. AML which has been refractory to two prior induction attempts
    3. ALL which has relapsed after Complete Remission
    4. ALL which has been refractory to two prior induction attempts
  • Disease status allows delay of additional anti-leukemia therapy for the duration of the study (hydroxyurea is allowed for control of WBC throughout study)
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-3
  • Able to adhere to the study visit schedule and other protocol requirements
  • Cardiac ejection fraction ≥45% by ECHO
  • Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN
  • Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy.

Exclusion Criteria:

  • Concurrent use of conventional or investigational anticancer agents, except hydroxyurea (Standard prophylactic anti-infectives and medications to prevent/treat tumor lysis syndrome are allowed. Hydroxyurea may be used to keep the WBC<25,000. Additional anti-leukemia therapy is prohibited during the study.).
  • Patient has received chemotherapy or radiotherapy within 2 weeks prior to entering the study or has not recovered from adverse events due to agents administered more than 2 weeks earlier, with the exception of hydroxyurea.
  • Patients with known active uncontrolled central nervous system (CNS) leukemia
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to daunorubicin
  • Patients with a total lifetime anthracycline exposure exceeding the equivalent of 900 mg/m2 of daunorubicin
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Unwilling or unable to undergo serial bone marrow aspirate/biopsy
  • Pregnant or nursing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02914977


Locations
Layout table for location information
United States, Kansas
University of Kansas Cancer Center - Clinical Research Center
Fairway, Kansas, United States, 66205
Sponsors and Collaborators
Tara Lin
Investigators
Layout table for investigator information
Principal Investigator: Tara Lin, MD University of Kansas Medical Center

Layout table for additonal information
Responsible Party: Tara Lin, Medical Doctor, University of Kansas Medical Center
ClinicalTrials.gov Identifier: NCT02914977     History of Changes
Other Study ID Numbers: IIT-2016-RP-HEM-LD-DNR
First Posted: September 26, 2016    Key Record Dates
Last Update Posted: June 24, 2019
Last Verified: June 2019
Keywords provided by Tara Lin, University of Kansas Medical Center:
Relapsed
Refractory
Additional relevant MeSH terms:
Layout table for MeSH terms
Antibiotics, Antineoplastic
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Neoplasms
Leukemia, Lymphoid
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Daunorubicin
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action